RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model.

scientific article published on 25 February 2013

RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1182/BLOOD-2012-06-434365
P932PMC publication ID3637015
P698PubMed publication ID23440244
P5875ResearchGate publication ID235729848

P50authorJerry PelletierQ85559340
Ola LarssonQ42738485
Cornelius MiethingQ49499854
P2093author name stringFrank Grosse
Scott W Lowe
Maria Zannis-Hadjopoulos
Teresa Lee
Hengli Tang
John R Mills
Domenic Di Paola
Abba Malina
P2860cites workDifferential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic functionQ24293924
c-Myc accelerates S-phase and requires WRN to avoid replication stressQ27347951
Altering chemosensitivity by modulating translation elongationQ27349402
p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxaQ28204059
Overexpression of a protein fragment of RNA helicase A causes inhibition of endogenous BRCA1 function and defects in ploidy and cytokinesis in mammary epithelial cellsQ28210468
Non-transcriptional control of DNA replication by c-MycQ28307758
An inhibitor of Bcl-2 family proteins induces regression of solid tumoursQ29547595
The landscape of somatic copy-number alteration across human cancersQ29547648
Mitochondria and cell death: outer membrane permeabilization and beyondQ29615459
Human DHX9 helicase unwinds triple-helical DNA structuresQ30090219
ATR and ATM differently regulate WRN to prevent DSBs at stalled replication forks and promote replication fork recoveryQ33292088
Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells.Q54679983
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceQ57338722
Nuclear DNA helicase II (RNA helicase A) interacts with Werner syndrome helicase and stimulates its exonuclease activityQ64388715
Cancer proliferation gene discovery through functional genomics.Q33317743
Heterochromatin on the inactive X chromosome delays replication timing without affecting origin usageQ33781572
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.Q33806087
Reversible tumorigenesis by MYC in hematopoietic lineagesQ33874286
Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also BimQ34450473
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapyQ34478557
Apoptosis and chemoresistance in transgenic cancer modelsQ34563810
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastomaQ34602599
BCL-2 family antagonists for cancer therapyQ34891196
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesisQ35208288
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.Q35250940
Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppressionQ35676910
Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphomaQ35828796
Proteome-wide identification of WRN-interacting proteins in untreated and nuclease-treated samples.Q36101151
Dissecting eIF4E action in tumorigenesisQ36209711
DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulationQ36578949
mTORC1 promotes survival through translational control of Mcl-1.Q36825427
Topoisomerase-specific drug sensitivity in relation to cell cycle progressionQ36920787
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomasQ36970689
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survivalQ37351043
A unified model of mammalian BCL-2 protein family interactions at the mitochondria.Q39292731
Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer CellsQ39470889
Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cellsQ39490308
Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.Q39577068
Werner syndrome protein limits MYC-induced cellular senescenceQ39895677
Fine mapping and functional activity of the adenosine deaminase origin in murine embryonic fibroblastsQ40027428
The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatinQ40041107
Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.Q41847989
Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesisQ41860419
WRN helicase unwinds Okazaki fragment-like hybrids in a reaction stimulated by the human DHX9 helicaseQ42004182
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.Q42064781
MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiencyQ43097729
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.Q43561629
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemiaQ46247309
Analysis of DNA content and BrdU incorporationQ46390380
P433issue17
P407language of work or nameEnglishQ1860
P304page(s)3402-3412
P577publication date2013-02-25
P1433published inBloodQ885070
P1476titleRNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model
P478volume121

Reverse relations

cites work (P2860)
Q90288686A DHX9-lncRNA-MDM2 interaction regulates cell invasion and angiogenesis of cervical cancer
Q37413655DHX33 Transcriptionally Controls Genes Involved in the Cell Cycle
Q33761586Dependence of p53-deficient cells on the DHX9 DExH-box helicase
Q35611388Detection of Tumor Suppressor Genes in Cancer Development by a Novel shRNA-Based Method
Q64104320Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy
Q38260741Genotoxic stress inhibits Ewing sarcoma cell growth by modulating alternative pre-mRNA processing of the RNA helicase DHX9.
Q46606403Nol12 is a multifunctional RNA binding protein at the nexus of RNA and DNA metabolism.
Q39146122Nucleic acid sensing pattern recognition receptors in the development of colorectal cancer and colitis.
Q38105300Perturbations of RNA helicases in cancer
Q47605047Polysome-profiling in small tissue samples
Q35097968RNA helicase A activity is inhibited by oncogenic transcription factor EWS-FLI1.
Q37685283RNA helicase DHX9 may be a therapeutic target in lung cancer and inhibited by enoxacin
Q36799279Repression of p53-target gene Bbc3/PUMA by MYSM1 is essential for the survival of hematopoietic multipotent progenitors and contributes to stem cell maintenance
Q40098712Suppression of Transposable Elements in Leukemic Stem Cells
Q33112680Suppression of the DHX9 helicase induces premature senescence in human diploid fibroblasts in a p53-dependent manner.
Q26765181The RNA helicase A in malignant transformation
Q26749166The biology of DHX9 and its potential as a therapeutic target
Q42124282The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas
Q91620218The sequence features that define efficient and specific hAGO2-dependent miRNA silencing guides
Q37256287Tumor cell survival dependence on the DHX9 DExH-box helicase
Q33651791Use of RNAi screens to uncover resistance mechanisms in cancer cells and identify synthetic lethal interactions

Search more.